Relationship between Carnitine Pharmacokinetics and Fatigue in Patients Treated with Cisplatin-Containing Chemotherapy

Oncol Res Treat. 2017;40(1-2):42-45. doi: 10.1159/000455255. Epub 2017 Jan 25.

Abstract

Background: Approximately 70% of the patients who receive chemotherapy suffer from fatigue, which lowers their quality of life and also has a negative influence on therapeutic efficacy. Previous studies have suggested a relationship between blood carnitine levels and fatigue. We conducted a prospective observational study to examine the relationship between carnitine pharmacokinetics and chemotherapy-induced fatigue in patients receiving cancer chemotherapy regimens that include cisplatin.

Patients and methods: 11 patients receiving chemotherapy including cisplatin (60-80 mg/m2) were included in the study. We performed 24-h urine collections and took blood samples on day 1 (before the initiation of chemotherapy) and days 2, 3, 4, and 8 in order to measure the carnitine concentrations in the serum and urine. These were compared with measures of self-reported fatigue. The primary endpoint was the change in self-reported fatigue subscales from baseline to day 8.

Results: Urinary carnitine concentrations differed significantly on days 2 and 3 (p = 0.003). The Functional Assessment of Chronic Illness Therapy-Fatigue scale version 4A score on day 8 indicated significantly higher levels of fatigue as compared to day 1 (p = 0.013).

Conclusion: This study suggests that there is an association between urinary carnitine levels and self-reported fatigue.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / chemical synthesis*
  • Antineoplastic Agents / therapeutic use
  • Carnitine / pharmacokinetics*
  • Carnitine / urine
  • Cisplatin / adverse effects*
  • Cisplatin / therapeutic use
  • Fatigue / blood
  • Fatigue / chemically induced*
  • Fatigue / urine
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasms / drug therapy*
  • Prospective Studies
  • Time Factors
  • beta 2-Microglobulin / urine

Substances

  • Antineoplastic Agents
  • beta 2-Microglobulin
  • Cisplatin
  • Carnitine